UNCY
HEALTHCAREUnicycive Therapeutics Inc
Live · NASDAQ · May 8, Close
What's Moving UNCY Today?
No stock-specific AI insight has been generated for UNCY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.13
Fundamentals
Trading
UNCY News
20 articles- Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 9, 2026
- Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech SummitYahoo Finance·Feb 4, 2026
- UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionYahoo Finance·Jan 29, 2026
- Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionYahoo Finance·Jan 29, 2026
- Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)Yahoo Finance·Dec 29, 2025
- Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In GrowthYahoo Finance·Dec 29, 2025
- Unicycive Therapeutics to Participate in Upcoming Investor Events in DecemberYahoo Finance·Nov 25, 2025
- Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as wellYahoo Finance·Nov 18, 2025
- Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 12, 2025
- Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Nov 3, 2025
- Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 ConferenceYahoo Finance·Oct 30, 2025
- Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-EndYahoo Finance·Oct 28, 2025
- When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit?Yahoo Finance·Oct 14, 2025
- Unicycive Therapeutics to Participate in Upcoming Investor Events in SeptemberYahoo Finance·Aug 26, 2025
- Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney DiseaseYahoo Finance·Aug 18, 2025
- Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 14, 2025
- Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of NephrologyYahoo Finance·Jul 24, 2025
- Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth?Yahoo Finance·Jul 22, 2025
- Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Jul 8, 2025
All 20 articles loaded
Price Data
52-Week Range
$8.13
Fundamentals
Trading
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to innovating treatments for kidney diseases, with a particular emphasis on addressing hyperphosphatemia. The company is advancing its proprietary therapies aimed at regulating phosphorus levels, which are pivotal in the management of kidney-related disorders. With a robust pipeline supported by a commitment to research and development, along with strategic partnerships to enhance its capabilities, Unicycive is well-positioned to drive significant advancements in nephrology. As its clinical trials progress, Unicycive presents a promising investment opportunity for institutional investors seeking exposure to transformative healthcare solutions.